These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 12773079)

  • 1. Combination ACE inhibitors and angiotensin II receptor blockers for hypertension.
    Finnegan PM; Gleason BL
    Ann Pharmacother; 2003 Jun; 37(6):886-9. PubMed ID: 12773079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial.
    Düsing R; Sellers F
    Curr Med Res Opin; 2009 Sep; 25(9):2287-301. PubMed ID: 19635044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
    Talbert RL
    J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension.
    Doulton TW; He FJ; MacGregor GA
    Hypertension; 2005 May; 45(5):880-6. PubMed ID: 15809363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines.
    Gales BJ; Bailey EK; Reed AN; Gales MA
    Ann Pharmacother; 2010 Feb; 44(2):360-6. PubMed ID: 20086184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined therapy with an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor in heart failure.
    Struckman DR; Rivey MP
    Ann Pharmacother; 2001 Feb; 35(2):242-8. PubMed ID: 11215846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination renin-angiotensin system blockade with the renin inhibitor aliskiren in hypertension.
    Doulton TW; MacGregor GA
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):185-9. PubMed ID: 19617273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renin-angiotensin-aldosterone system inhibition: overview of the therapeutic use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and direct renin inhibitors.
    Mercier K; Smith H; Biederman J
    Prim Care; 2014 Dec; 41(4):765-78. PubMed ID: 25439533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
    Schindler C
    Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II-receptor blockers: clinical relevance and therapeutic role.
    Rodgers JE; Patterson JH
    Am J Health Syst Pharm; 2001 Apr; 58(8):671-83. PubMed ID: 11329759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term persistence to mono and combination therapies with angiotensin converting enzymes and angiotensin II receptor blockers in Australia.
    Gadzhanova S; Roughead EE; Bartlett LE
    Eur J Clin Pharmacol; 2016 Jun; 72(6):765-71. PubMed ID: 26961086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Review of ACE Inhibitors and ARBs in Black Patients With Hypertension.
    Helmer A; Slater N; Smithgall S
    Ann Pharmacother; 2018 Nov; 52(11):1143-1151. PubMed ID: 29808707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual blockade of the renin-angiotensin system in diabetic nephropathy.
    Wade VL; Gleason BL
    Ann Pharmacother; 2004; 38(7-8):1278-82. PubMed ID: 15187210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective electronic chart review of blood pressure changes in elderly patients treated with amlodipine or an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker.
    Dollar A; Brown C; Putnam D; McLaughlin T; Okamoto L; Arocho R
    Clin Ther; 2002 Jun; 24(6):930-41. PubMed ID: 12117083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mega clinical trials which have shaped the RAS intervention clinical practice.
    Düsing R
    Ther Adv Cardiovasc Dis; 2016 Jun; 10(3):133-50. PubMed ID: 27271312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.